Drug Target Review

OCTOBER 24, 2024

Data-driven discovery As with many early-stage biotech companies, Five Alarm Bio is highly data-driven, producing vast amounts of experimental data through cell-based assays and phenotypic screening. She founded Pellis Care Ltd and in 2022 joined Five Alarm Bio Ltd as CEO.

Cell Based Assays 52

Cell Based Assays Science Disease Doctors 52

The Premier Consulting Blog

APRIL 3, 2024

Technology Selection Description of which technology was selected (HPLC, SDS-PAGE, cell-based assay, ELISA, etc.) and a rationale for selecting it (could be based on development studies, prior knowledge, literature, etc.). ICH Harmonised Guideline. Analytical Procedure Development Q14. ICH Harmonised Guideline.

Pharmaceuticals 52

Pharmaceuticals Cell Based Assays Production International 52

Drug Target Review

JULY 6, 2023

allowing researchers to use “certain alternatives to animal testing, including cell-based assays and computer models, to obtain an exemption from the FDA to investigate the safety and effectiveness of a drug.” A new research paper, co-authored by PETA Science Consortium International e.V., Annals of Internal Medicine.

Animal Testing 105

Animal Testing Drugs Clinical Trials Clinical Research 105

The Pharma Data

OCTOBER 15, 2020

ASLAN003 is a highly selective and potent inhibitor of human DHODH (IC 50 = 35 nM) and has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme in cell free and cell-based assays than the first generation inhibitor teriflunomide. In 2019, ASLAN completed a Phase 2 study testing ASLAN003 in AML.

Pharmaceuticals 40

Pharmaceuticals Cell Based Assays Clinical Development Treatment 40

Agency IQ

APRIL 12, 2024

Cell-based assays , while more complex to develop and use, offer another option for characterizing product activity at a slightly higher level, allowing sponsors to measure the further downstream effects of products (e.g., morphological cell changes or alterations in protein production or expression).

Production 40

Production FDA Therapies Biochemical Assays 40

Drug Target Review

MAY 3, 2024

Ultimately, multi-omics represents an opportunity to generate high-fidelity, richly informative datasets that are often internally orthogonal. At Beckman Coulter Life Sciences , he supports the applications development team in NGS, cell-based assays, and proteomics workflows. So why doesn’t everyone do it?

Research 116

Research Science Cell Based Assays Disease 116